Get 50% OFF This Summer!
Windlas Biotech
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.
The company has state-of-the-art manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.
The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries.
Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders.
The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products.
Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible.
To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.
Windlas Biotech share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Windlas Biotech indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Windlas Biotech is valued compared to its competitors.
Windlas Biotech PE ratio helps investors understand what is the market value of each stock compared to Windlas Biotech 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Windlas Biotech evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Windlas Biotech generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Windlas Biotech in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Windlas Biotech shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Windlas Biotech compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Windlas Biotech over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Windlas Biotech helps investors get an insight into when they can enter or exit the stock. Key components of Windlas Biotech Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Windlas Biotech shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Windlas Biotech ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Windlas Biotech provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Windlas Biotech highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Windlas Biotech .
The balance sheet presents a snapshot of Windlas Biotech ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App